Trials / Completed
CompletedNCT00506077
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0249 | MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days. |
| DRUG | Comparator: Placebo (unspecified) | MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-07-25
- Last updated
- 2015-08-03
- Results posted
- 2011-03-07
Source: ClinicalTrials.gov record NCT00506077. Inclusion in this directory is not an endorsement.